Ceragenix Pharmaceuticals, Inc. (CGXP) news stock charts
Ceragenix Pharmaceuticals, Inc. (CGXP/CGXP.OB) Investment Summary:
Ceragenix Pharmaceuticals, Inc. operates as a biopharmaceutical and medical device company focusing on infectious diseases and dermatology in the United States. The company has two base technology platforms, which include Ceragenins for the treatment of infectious disease; and Barrier Repair for the treatment of dermatological disorders, including atopic dermatitis, neonatal skin disorders and others. Its Ceragenin compounds are active against a range of gram positive and negative bacteria. The company uses its Ceragenin technology to formulate Cerashield antimicrobial coatings for medical devices. Its Barrier Repair technology is the platform for the development of two prescription topical ...CERAGENIX PHARMACEUTICALS IN (CGXP:OTC Bulletin Board Market)
Snapshot of CERAGENIX PHARMACEUTICALS IN (CGXP)
|
OPEN
$0.40
|
PREVIOUS CLOSE
$0.40
|
|
|
DAY HIGH
$0.41
|
DAY LOW
$0.21
|
|
|
52 WEEK HIGH
10/27/09 - $0.70
|
52 WEEK LOW
03/17/10 - $0.21
|
|
|
MARKET CAP
7.3M
|
AVERAGE VOLUME 10 D
3.0K
|
|
|
EPS TTM
$-0.05
|
SHARES OUTSTANDING
18.2M
|
|
|
CGXP Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
Key developments for CERAGENIX PHARMACEUTICALS IN (CGXP)
Ceragenix Pharmaceuticals, Inc. announced that it has entered into an exclusive distribution and supply agreement with BexPharm Pharmaceuticals, Inc. to commercialize EpiCeram(r), a prescription topical cream for treating atopic dermatitis and other dry skin conditions, in South Korea. The Agreement grants BexPharm exclusivity in the Territory for the distribution and marketing of EpiCeram(r) while Ceragenix will be responsible for the manufacturing and supply of the product. BexPharm is also responsible for obtaining regulatory clearance to market EpiCeram(r) in the Territory. Financial terms were not disclosed.
Ceragenix Pharmaceuticals, Inc. has entered into an exclusive distribution and supply agreement with BioPro Pharmaceutical, Inc. (BioPro) to commercialize EpiCeram(R), a prescription topical cream for treating atopic dermatitis and other dry skin conditions, in Hong Kong and Taiwan (the territories). The agreement grants BioPro exclusivity in the Territories for the distribution and marketing of EpiCeram(R) while Ceragenix will be responsible for the manufacturing and supply of the product. BioPro is also responsible for obtaining regulatory clearance to market EpiCeram(R) in the Territories. Financial terms were not disclosed.
Ceragenix Pharmaceuticals Inc. provided an update to a previously announced exclusive cooperative research and development with MAST Biosurgery Inc. for the development of one or more new surgical products incorporating Ceragenix's CeraShield(TM) antimicrobial technology. Ceragenix announced that based on its evaluation activities undertaken to-date, MAST has decided to invoke its right to negotiate commercialization terms pursuant to the terms of the Agreement. Under the terms of the Agreement, MAST has an exclusive sixty (60) day period to negotiate a license agreement for the Cerashield(TM) technology within the field of use as defined in the Agreement. There is no assurance that the parties will be able to reach an agreement on the terms of a license agreement.
Ceragenix Pharmaceuticals, Inc. financial resources
CGXP Competitors
| Company | Last | Change |
| Helix Biomedix Inc | $0.25 USD | -0.15 |
| Inhibitex Inc | $1.30 USD | -0.06 |
| Novabay Pharmaceuticals Inc | $2.08 USD | -0.07 |
| PolyMedix Inc | $1.22 USD | +0.04 |
| Senetek PLC | $0.98 USD | 0.00 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | CGXP | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 3.6x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | NM | Not Meaningful |
|
CGXP |
||
CGXP transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent Financial News About Ceragenix Pharmaceuticals, Inc.
Ceragenix and BexPharm Enter Into Distribution and Supply Agreement for EpiCeram(R)
Read article
Ceragenix and BexPharm Enter Into Distribution and Supply Agreement for EpiCeram(R)
Read article
Ceragenix and BioPro Enter into Distribution and Supply Agreement for EpiCeram®
Read article
Ceragenix and BioPro Enter into Distribution and Supply Agreement for EpiCeram®
Read article
CERAGENIX PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events
Read article
CERAGENIX PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
Read article
CERAGENIX PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
Read article
CERAGENIX PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Read article
CERAGENIX PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Read article
NIH Issues $2.87 Million Grant for Development of Ceragenin Based Drug to Treat Clostridium difficile and Shigella Gastrointestinal Infections
Read article
Partner Exercises Option for Exclusive Period to Negotiate Licensing Terms for CeraShield Antimicrobial Coating Application
Read article
Second Partner Exercises Option for Exclusive Period to Negotiate Licensing Terms for CeraShield Antimicrobial Coating Application
Read article
CERAGENIX PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
Read article